Cases & Deals

  • Home
  • Practices
  • Cellectis sells Swedish subsidiary Cellectis AB to Takara Bio

Share

Cellectis sells Swedish subsidiary Cellectis AB to Takara Bio

September 2014

Client(s) Cellectis SA

Jones Day advised Cellectis, a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART), in the sale of its subsidiary Cellectis AB to Takara Bio Inc.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.